News

G.ST Antivirals reports start of Phase II trial and announces appointment of Ronald Bruce Turner as new Chief Medical Officer

Download PDFRead article→

G.ST Antivirals reports positive Phase I trial results for 2-Deoxy-D-glucose against upper respiratory infections

Download PDFRead article→

Results of collaboration between G.ST Antivirals and Takeda Global Pathogen Safety are published in The Journal of Virus Eradication and substantiate efficacy of 2-Deoxyglucose against respiratory tract pathogens

Read article→

G.ST Antivirals nominated among the top 10 for the Bridging Science & Business Award of the Rudolf Sallinger Foundation

Read article→

G.ST Antivirals reaches a major milestone in the development of its lead asset and begins clinical phase I at the Vienna General Hospital

See APA OTS Press release→

G.ST Antivirals to expand its innovative host cell-based treatment approach to COPD exacerbations after succeeding in highly competitive Life science call of the Vienna Business Agency

Read article→

CEO and Co-founder Guido Gualdoni talked at the Gründer&Zünder Podcast about the exciting path from scientific findings to starting a biotech company

See Podcast episode →

G.ST Antiviral's founder gave an encouraging interview about the obstacles and joys of founding a university spin-off (in German)

See Article on News.at→

Founders of G.ST Antivirals Guido Gualdoni and Johannes Stöckl are “Inventors of the Year 2020” of the Medical University of Vienna

See Press release→

G.ST Antivirals among the nominees for the Phönix Gründerpreis of the Austrian Promotional Bank (AWS) in the category Spin-off

See Website Phönix Gründerpreis→

Viennese biotech startup G.ST Antivirals gets funding for viral disease therapies

See Press article→

G.ST Antivirals and Takeda start research cooperation on antivirals against COVID-19

See Press release→